NFX88

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Comparator or background therapy1 trial
Phase 2	NCT04148573 Comparator	Oct 2019 → May 2022	neuropathy, painful, spinal cord injury	Neurofix S.L.	Completed	No outcome recorded

Date	Issuer	Release
2022-07-04	Neurofix S.L.	Concluye con éxito la fase IIA del pionero fármaco español contra el dolor crónico por lesión medular, el NFX88 de Neurofix Pharma neurofixpharma.com ↗
2021-05-04	Neurofix S.L.	Antonio Oliviero: “El ensayo con NFX88 da una esperanza a los pacientes que no han conseguido un tratamiento satisfactorio de su dolor” neurofixpharma.com ↗
2020-07-21	Neurofix S.L.	Neurofix y su fármaco NFX88, protagonistas en Televisión Castilla y León neurofixpharma.com ↗

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	NFX88	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04148573 ↗
Route	Oral	“daily oral treatment with NFX88” NCT04148573 ↗